• Early data support panobinostat benefit in high-risk AML

    More than 4 in 10 patients achieved complete remission.

  • EMA approves gilteritinib for AML with a FLT3 mutation
    EMA approves gilteritinib for AML with a FLT3 mutation

    Gilteritinib has been shown to improve overall survival compared to salvage chemotherapy in this patient group.

  • Pediatric AML: risk for cytogenetic abnormalities rises with BMI

    BMI was not associated with treatment-related or overall mortality.

  • AML: new transplant protocol offers favorable survival, GVHD prophylaxis

    6 in 10 patients remained relapse-free at 1 year.

  • Myeloid leukemias, CLL rising sharply in baby boomers

    78% increase in leukemias in 1998-2018.

  • AML: relapse within 3 months of transplant portends poor survival

    More than 4 in 10 achieved CR with reinduction chemotherapy.

  • AML: add-on nivolumab safe, effective with standard induction therapy

    Median EFS not reached at time of analysis.

  • Frontline AML: real-world data confirm decitabine safety, efficacy

    Adverse cytogenetics, higher WBC predicted inferior survival.

  • MDS: certain demographic factors prognostic of favorable survival

    Factors including married status prognostic of favorable survival.

  • Elderly AML: which factors predict in-hospital mortality after ICU admission?

    Findings may help inform critical decision-making.

  • Pediatric AML: clofarabine regimen spares anthracyclines, maintains survival

    No significant difference in 3-year event-free survival and OS.

  • AML/MDS: lower-dose conditioning effective in older patients receiving CBT

    Regimen supported early recovery, high neutrophil engraftment.

  • EHA 2019 – Gilteritinib, a new treatment paradigm for relapsed/refractory acute myeloid leukaemia

    The final results of the ADMIRAL trial highlight the value of gilteritinib monotherapy for adult patients harbouring FLT3-mutations

  • EHA 2019 – Outcomes after different intensity of conditioning in acute myeloid leukaemia: the importance of genomic variants

    The worse survival rates observed after reduced-intensity conditioning are limited to individuals with genomic evidence of residual disease prior to transplant.

  • Load more